MA
REGN icon

MCF Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

MCF Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7K Sell
30
-12
-29% -$8.17K ﹤0.01% 913
2026
Q1 		$32.5K Sell
42
-3
-7% -$2.3K ﹤0.01% 702
2025
Q4 		$34.7K Buy
45
+15
+50% +$10.2K ﹤0.01% 575
2025
Q3 		$16.9K Hold
30
– – ﹤0.01% 608
2025
Q2 		$15.8K Hold
30
– – ﹤0.01% 589
2025
Q1 		$19K Sell
30
-6
-17% -$4.13K ﹤0.01% 561
2024
Q4 		$25.6K Hold
36
– – ﹤0.01% 509
2024
Q3 		$37.8K Sell
36
-5
-12% -$5.56K ﹤0.01% 437
2024
Q2 		$43.1K Buy
41
+6
+17% +$5.82K ﹤0.01% 410
2024
Q1 		$33.7K Sell
35
-1
-3% -$951 ﹤0.01% 443
2023
Q4 		$31.6K Buy
36
+12
+50% +$9.88K ﹤0.01% 440
2023
Q3 		$19.8K Hold
24
– – ﹤0.01% 488
2023
Q2 		$17.2K Hold
24
– – ﹤0.01% 497
2023
Q1 		$19.7K Buy
24
+20
+500% +$15.1K ﹤0.01% 475
2022
Q4 		$2.89K Hold
4
– – ﹤0.01% 642
2022
Q3 		$3K Hold
4
– – ﹤0.01% 653
2022
Q2 		$2K Hold
4
– – ﹤0.01% 640
2022
Q1 		$3K Buy
+4
New +$2.53K ﹤0.01% 613
2021
Q4 		– Sell
-4
Closed -$2K – 529
2021
Q3 		$2K Buy
+4
New +$2.48K ﹤0.01% 630

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

MCF Advisors's REGN Position: Q2 2026 in Review

MCF Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 29% in Q2 2026, selling an estimated $8.17K and leaving 30 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #913.

MCF Advisors first reported a position in REGN in Q3 2021 and has held it in 19 quarters since. The position peaked at $43.1K in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • MCF Advisors held 30 shares of Regeneron Pharmaceuticals worth $18.7K as of Q2 2026.
  • MCF Advisors sold 12 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.17K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #913 holding.
  • MCF Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • MCF Advisors's Regeneron Pharmaceuticals position peaked at $43.1K in Q2 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.